



EHA2022 abstracts: What's hot in MPN?

To help navigate the exciting content being presented at the EHA2022 Congress, the MPN Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MPN.



Click
the abstracts
to view

This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at <https://mpn-hub.com>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.



Scientific Education Support

Clinical trial data

P1029	<u>Matching-adjusted indirect comparison (MAIC) of pelabresib (CPI-0610) in combination with ruxolitinib vs ruxolitinib or fedratinib monotherapy in patients with intermediate or high-risk myelofibrosis</u>
P1033	<u>A phase 2 study of the LSD1 inhibitor IMG-7289 (bomedemstat) for the treatment of essential thrombocythemia (ET)</u>
P1050	<u>Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM]</u>
P1070	<u>Navitoclax monotherapy in patients with myelofibrosis previously treated with JAK-2 inhibitors: safety and tolerability</u>
S195	<u>MOMENTUM: phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor</u>
S196	<u>Ropeginterferon alfa-2b achieves patient-specific treatment goals in polycythemia vera: final results from the PROUD-PV/CONTINUATION-PV studies</u>
S197	<u>Navitoclax plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: preliminary safety and efficacy in a multicenter, open-label phase 2 study</u>
S198	<u>BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis — JAK inhibitor-naïve or with suboptimal response to ruxolitinib — preliminary data from the manifest study</u>

Real-word data

P1013	<u>Overall survival in patients with systemic mastocytosis with associated hematologic neoplasm treated with avapritinib versus best available therapy</u>
P1014	<u>Overall survival in patients with advanced systemic mastocytosis receiving avapritinib versus midostaurin or cladribine</u>
P1043	<u>Outcome of patients with prefibrotic myelofibrosis from a large academic center</u>
P1062	<u>A real-world evaluation of the association between elevated blood counts and thrombotic events in polycythemia vera: An analysis of data from the REVEAL study</u>
S199	<u>A national retrospective cohort study of MPN-SVT: results from the UK Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis (MASCOT) Registry</u>

MPN and COVID-19

P1009	<u>Predictors of hospitalization and severe outcomes in patients with MPN and COVID-19</u>
P1011	<u>Predictors of COVID-19 disease and survival to COVID-19 in MPN patients treated with ruxolitinib</u>

Translational data

S190	<u>ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis mediated inflammation and fibrocyte generation in myeloproliferative neoplasms</u>
S191	<u>Calreticulin-mutated hematopoietic cells are vulnerable to the combined inhibition of the proteasome and the IRE1A-XBP1 axis of the unfolded protein response</u>
S192	<u>Single-cell RNA profiling of myelofibrosis patients reveals pelabresib-induced decrease of megakaryocytic progenitors and normalization of CD4+ T cells in peripheral blood</u>
S193	<u>Genomic and functional impact of TP53 inactivation in JAK2V617F myeloproliferative neoplasms: A transgenic mouse model approach</u>



Follow us on Twitter to keep up to date
with the latest from the EHA2022
Congress!

@MPN_Hub
#EHA2022
mpn-hub.com